A method for analyzing a blood specimen, comprising the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system and a reagent for measuring an activated partial thromboplastin time (APTT) to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform, which further comprises a step of acquiring at least one parameter value based on a rate waveform obtained by primary differentiation of the coagulation waveform, and acquires the information regarding fibrinolytic capacity of the blood specimen based on the acquired parameter value, wherein the coagulation waveform is acquired from optical information obtained by irradiating the measuring sample with light, wherein a parameter regarding differentiation of the coagulation waveform is at least one selected from the group consisting of maximum fibrinolysis rate (|max 1|), inclination I, inclination II, FL time, area, and time of reaching the maximum fibrinolysis rate, which comprises: comparing parameter values regarding differentiation of the acquired coagulation waveform with normal ranges corresponding to the parameter values; and acquiring, as the information regarding fibrinolytic capacity of the blood specimen, information that fibrinolytic system in the blood specimen has an abnormality when at least one of the parameter values regarding differentiation of the acquired coagulation waveform is outside a normal range corresponding to the parameter, wherein the normal range is a range of values of the respective parameters that can be shown by a blood specimen of a healthy subject, wherein when the information that fibrinolytic system in the blood specimen has an abnormality is obtained, information about which of α2-antiplasmin (α2AP) deficiency, plasminogen activator inhibitor-1 (PAI-1) deficiency, or plasminogen deficiency is a cause of the abnormality is further acquired. coagulating a blood specimen in the presence of an activating agent for fibrinolytic system and a reagent for measuring an activated partial thromboplastin time (APTT) to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform, which further comprises a step of acquiring at least one parameter value based on a rate waveform obtained by primary differentiation of the coagulation waveform, and acquires the information regarding fibrinolytic capacity of the blood specimen based on the acquired parameter value, comparing parameter values regarding differentiation of the acquired coagulation waveform with normal ranges corresponding to the parameter values; and acquiring, as the information regarding fibrinolytic capacity of the blood specimen, information that fibrinolytic system in the blood specimen has an abnormality when at least one of the parameter values regarding differentiation of the acquired coagulation waveform is outside a normal range corresponding to the parameter, wherein the normal range is a range of values of the respective parameters that can be shown by a blood specimen of a healthy subject, wherein when the information that fibrinolytic system in the blood specimen has an abnormality is obtained, information about which of α2-antiplasmin (α2AP) deficiency, plasminogen activator inhibitor-1 (PAI-1) deficiency, or plasminogen deficiency is a cause of the abnormality is further acquired. <EOS>